Fosun's revised Gland takeover plan no longer needs Indian approval

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmaceutical drug Pharmacology

Shanghai Fosun Pharma says it no longer requires the Indian Government's permission to buy a majority stake in Gland Pharma.

In an emailed statement Fosun told us it will buy 74% stake in Gland for $ 1.1bn (€912.6bn) and set a termination date for the deal of October 3.

The Hong Kong Stock Exchange listed firm said: “The stake of Gland Pharma held by KKR Floorline Investment Pte. Ltd. and the Founder Shareholders that will be acquired by Fosun Pharma is adjusted from 69.971% to 57.891%​.”

After the transaction is completed, KKR will no longer own shares in Gland Pharma​.”

Government approval

Fosun announced its intention to buy Gland from founders and US investment group KKR in July​ last year, originally stateing that it would acquire an 86% stake in the Indian firm.

In August​ this year Fosun said India’s Foreign Investment Promotion Board (FIPB) had referred the takeover plan to the Government’s Cabinet Committee on Economic Affairs for review.

At the time a Fosun spokeswoman told us “The acquisition obtained prior approval from relevant PRC [People’s Republic of China] authorities, and is pending review and approval from the Cabinet Committee on Economic Affairs of India.”

Under rules​ introduced this year, any foreign investor that wants to buy an Indian drug manufacturer needs to seek Government approval if it plans to buy more that 74% of the target company's shares.

API supply

Gland makes injectable drugs, both own-brand medicines and for other firms on a contractual basis. It operates four facilities in India that produce active pharmaceutical ingredients (API) and finished dosage formulations.

The firm is a major supplier of the API heparin to hospitals in India.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more